Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pherecydes Pharma SA

Developing bacterial phages as anti-infectives

This article was originally published in Start Up

Executive Summary

Scientists have long realized that certain viruses can destroy bacteria. Classified as bacteriophages, these viruses attach to specific receptors on the surface of bacteria and inject their own genetic material. Some so-called lytic phages kill their hosts right away and their progeny replicate as soon as the bacteria are lysed, or ruptured. Pherecydes Pharma SA, a start-up based in Romainville, France, is working to identify and modify large numbers of lytic phages, with the goal of creating therapies effective against antibiotic-resistant nosocomial infections.

You may also be interested in...



Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases

Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC092283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel